Poultry Pharmaceuticals Market By product type -
Poultry Pharmaceuticals Market By Animal Type -
Poultry Pharmaceuticals Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Poultry Pharmaceuticals Market Snapshot
Chapter 4. Global Poultry Pharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. By Product Type, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product Type:
5.2.1. Drugs
5.2.1.1. VETRIMOXIN
5.2.1.2. Other Drug Products
5.2.2. Vaccines
5.2.2.1. INNOVAX
5.2.2.2. NOBILIS
5.2.2.3. Poulvac
5.2.2.4. Other Vaccine Products
5.2.3. Feed Additives
5.2.3.1. VIGOSINE
5.2.3.2. Amnovit
5.2.3.3. Other Feed Additives
Chapter 6. Market Segmentation 2: By Animal Type Estimates & Trend Analysis
6.1. By Animal Type & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Animal Type:
6.2.1. Chicken
6.2.2. Turkey
6.2.3. Duck
6.2.4. Goose
6.2.5. Others
7.1. Global Poultry Pharmaceuticals Market , Regional Snapshot 2023 & 2031
7.2. North America
Chapter 7. Poultry Pharmaceuticals Market Segmentation 3: Regional Estimates & Trend Analysis
7.2.1. North America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2024-2031
7.2.3. North America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Product type, 2024-2031
7.3. Europe
7.3.1. Europe Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2024-2031
7.3.3. Europe Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Product type, 2024-2031
7.4. Asia Pacific
7.4.1. Asia Pacific Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2024-2031
7.4.3. Asia Pacific Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts By Product type, 2024-2031
7.5. Latin America
7.5.1. Latin America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2024-2031
7.5.3. Latin America Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Product type, 2024-2031
7.6. Middle East & Africa
7.6.1. Middle East & Africa Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2024-2031
7.6.3. Middle East & Africa Poultry Pharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Product type, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Aervoe Industries Inc.
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Overview
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Bayer AG,
8.2.3. Bimeda
8.2.4. Ceva Sante Animale
8.2.5. Elanco Animal Health (Eli Lilly and Company)
8.2.6. Merck Animal Health
8.2.7. Merial Animal Health (Sanofi)
8.2.8. Virbac
8.2.9. Boehringer Ingelheim
8.2.10. Zoetis, Inc.
8.2.11. Pacific GeneTech
8.2.12. Avivagen Inc.
8.2.13. Hester Biosciences Limited
8.2.14. Venkys India
8.2.15. Calier
8.2.16. KM Biologics
8.2.17. Others
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.